These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16133115)

  • 1. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
    Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
    Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.
    Kim CH; Hong MJ; Park SD; Kim CK; Park MY; Sohn HJ; Cho HI; Kim TG; Hong YK
    Cancer Immunol Immunother; 2006 Nov; 55(11):1309-19. PubMed ID: 16463038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
    Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
    J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
    Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
    Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioma stem cell-targeted dendritic cells as a tumor vaccine against malignant glioma.
    Ji B; Chen Q; Liu B; Wu L; Tian D; Guo Z; Yi W
    Yonsei Med J; 2013 Jan; 54(1):92-100. PubMed ID: 23225804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
    Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
    Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
    Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
    Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
    Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
    Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
    Xu M; Yao Y; Hua W; Wu Z; Zhong P; Mao Y; Zhou L; Luo F; Chu Y
    J Neurooncol; 2014 Feb; 116(3):497-504. PubMed ID: 24398615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based immunotherapy of malignant gliomas.
    Parajuli P; Sloan AE
    Cancer Invest; 2004; 22(3):405-16. PubMed ID: 15493362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
    Zhu S; Lv X; Zhang X; Li T; Zang G; Yang N; Wang X; Wu J; Chen W; Liu YJ; Chen J
    Int J Cancer; 2019 Jun; 144(11):2867-2879. PubMed ID: 30565657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
    Zhu X; Lu C; Xiao B; Qiao J; Sun Y
    J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
    Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
    J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.
    Jiang XB; Lu XL; Hu P; Liu RE
    Vaccine; 2009 Oct; 27(44):6210-6. PubMed ID: 19699331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma.
    Saito R; Mizuno M; Nakahara N; Tsuno T; Kumabe T; Yoshimoto T; Yoshida J
    Int J Cancer; 2004 Sep; 111(5):777-82. PubMed ID: 15252850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapies in neuro-oncology.
    Pellegatta S; Finocchiaro G
    Neurol Sci; 2005 May; 26 Suppl 1():S43-5. PubMed ID: 15883693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.